Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 25.19 million compared to USD 17.55 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.36 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.62 USD | -1.22% | -3.43% | -10.83% |
05-17 | Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing | MT |
05-16 | Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.83% | 4.24B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.32% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- NUVL Stock
- News Nuvalent, Inc.
- Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023